Arrowhead Pharmaceuticals

Quarterly Financials

Values in thousands 2025-06-30 2025-03-31 2024-12-31 2024-09-30
Revenue
$27,767
$542,709
$2,500
$23,589
Gross Profit
21,544
542,709
2,500
10,019
EBITDA
-165,550
397,339
-148,234
-153,126
EBIT
-171,773
391,255
-153,469
-158,151
Net Income
-175,241
370,445
-173,085
-170,536
Net Change In Cash
27,767
542,709
2,500
23,589
Free Cash Flow
-157,084
454,756
-153,788
-161,505
Cash
129,793
185,709
53,889
102,685
Basic Shares
139,039
134,484
124,848
121,991

Annual Financials

Values in thousands 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Revenue
$3,551
$240,735
$243,231
$138,287
Gross Profit
3,551
240,735
243,231
138,287
EBITDA
-561,513
-175,672
-168,086
-132,579
EBIT
-580,108
-188,165
-178,507
-140,846
Net Income
-599,493
-205,275
-176,494
-140,848
Net Change In Cash
3,551
240,735
243,231
138,287
Cost of Revenue
-76,362
40,851
Free Cash Flow
-604,320
-330,627
-188,908
147,657
Cash
102,685
110,891
108,005
184,434
Basic Shares
119,784
106,750
105,426
103,745

Earnings Calls

Quarter EPS
2025-09-30
$0
2025-06-30
-$1.26
2025-03-31
$2.75
2024-12-31
-$1.39